Semaglutide significantly slows the biological progression of a blood protein signature associated with an increased risk of developing dementia, according to a proteomics analysis published in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. The study evaluated adults aged 65 and older with overweight or obesity and established cardiovascular disease, offering new insight into how glucagon-like peptide-1 receptor agonists might influence neurological health over time.
Proteomics Analysis of the SELECT Trial
Researchers examined non-fasted serum samples from participants in the Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT) trial to determine how once-weekly subcutaneous injections of 2.4 mg semaglutide compared against a matched placebo. The analysis focused on 2,970 participants aged 65 and older who had available paired blood samples collected at both baseline and week 104, according to the study data published in August 2026. The investigation utilized the Dementia SomaSignal Test (dSST), a validated 25-protein plasma score designed to predict 5- and 20-year all-cause dementia risk through multi-pathway biological changes.
According to the published findings, semaglutide reduced increases in predicted dementia risk compared to placebo over the two-year period. Participants receiving the medication experienced a 2.5-fold smaller increase in 5-year predicted risk, translating to a 26.0% lower predicted event rate with an odds ratio of 0.74. For the 20-year risk horizon, semaglutide users showed a 1.67-fold smaller increase, representing an 8.8% lower predicted risk with an odds ratio of 0.91. Furthermore, the therapy reduced the odds of moving into a higher dementia risk classification by 36% compared to the placebo group.
Real-World Evidence in Type 2 Diabetes
These biological findings align with population-based observational research examining clinical diagnoses among patients managing metabolic disorders. In a target trial emulation study published in the Journal of Alzheimer’s Disease, investigators analyzed electronic health records of more than 1.71 million United States adults with type 2 diabetes to compare semaglutide against other glucose-lowering therapies.
According to the real-world data, semaglutide use was associated with a substantially lower incidence of first-time Alzheimer’s disease-related dementia diagnoses over a three-year follow-up. Specifically, semaglutide demonstrated a 46% lower risk of Alzheimer’s-related dementia compared to insulin, a 33% reduction compared to metformin, and a 20% lower risk relative to older-generation GLP-1 receptor agonists. The analysis noted that the most pronounced protective associations appeared in cases of vascular dementia, while no statistically significant links emerged for frontotemporal or Lewy body dementia subtypes.
The convergence of proteomics biomarker data and electronic health record analyses highlights the intersection of metabolic disease and neurodegeneration. According to the 2024 Lancet Commission on Dementia, conditions like obesity and type 2 diabetes function as major modifiable risk factors for cognitive decline. Because chronic inflammation, oxidative stress, and insulin resistance contribute to both metabolic dysfunction and cerebral pathology, researchers continue to study whether therapies targeting peripheral metabolic pathways can concurrently exert neuroprotective effects in the central nervous system.
Keep reading